(Q36133801)

12 August 2017

1 reference

title

Enfuvirtide: a review of its use in the management of HIV infection (English)

1 reference

12 August 2017

3

Greg Plosker

1 reference

12 August 2017

2

Gillian M Keating

1 reference

12 August 2017

Vicki Oldfield

1

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

65

1 reference

12 August 2017

issue

8

1 reference

12 August 2017

page(s)

1139-1160

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565080-00007

12 August 2017

exact match

0 references

cites work

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations

1 reference

12 December 2020

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

1 reference

12 December 2020

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection

1 reference

12 December 2020

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients

1 reference

12 December 2020

Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children

1 reference

12 December 2020

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

1 reference

12 December 2020

Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients

1 reference

12 December 2020

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.

1 reference

12 December 2020

Enfuvirtide (Fuzeon): the first fusion inhibitor.

1 reference

12 December 2020

Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20.

1 reference

12 December 2020

Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity

1 reference

12 December 2020

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

1 reference

12 December 2020

Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

1 reference

12 December 2020

Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships

1 reference

12 December 2020

1 reference

12 December 2020

Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane

1 reference

12 December 2020

Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

1 reference

12 December 2020

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

12 December 2020

Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

1 reference

12 December 2020

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

12 December 2020

PENTA guidelines for the use of antiretroviral therapy, 2004.

1 reference

12 December 2020

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

1 reference

12 December 2020

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

1 reference

12 December 2020

Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro

1 reference

12 December 2020

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

12 December 2020

Duration of Highly Active Antiretroviral Therapy Regimens

1 reference

12 December 2020

Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains

1 reference

12 December 2020

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

1 reference

12 December 2020

Immunological and virological study of enfuvirtide-treated HIV-positive patients

1 reference

12 December 2020

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients

1 reference

12 December 2020

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

1 reference

12 December 2020

CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro

1 reference

12 December 2020

Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children

1 reference

12 December 2020

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide

1 reference

12 December 2020

Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy

1 reference

12 December 2020

A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.

1 reference

12 December 2020

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

1 reference

12 December 2020

Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro

1 reference

12 December 2020

1 reference

12 December 2020

Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients

1 reference

12 December 2020

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

12 December 2020

Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20.

1 reference

12 December 2020

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks

1 reference

12 December 2020

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

1 reference

12 December 2020

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

12 December 2020

10.2165/00003495-200565080-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

1052197354

0 references

Fatcat ID

release_kev3nzlvbvas7m6rsmydyv5slm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kev3nzlvbvas7m6rsmydyv5slm

24 November 2022

mapped directly with Wikidata item

1 reference